Crystalvue Medical Co Ltd AI Stock Analysis
Crystalvue Medical Co Ltd (6527) AI Stock Analysis
Crystalvue Medical Co Ltd
(TPEx:6527)
Crystalvue Medical earns an above-average score driven primarily by its high-quality financial profile: consistent revenue growth, improving margins, record profits and an essentially debt-free balance sheet with ~79% equity funding. A low P/E of 11.9 paired with a 4.0% dividend yield adds valuation appeal. Holding the score back are weaker cash flow dynamics — operating cash flow declined year-over-year and elevated capital spending turned free cash flow negative — along with a technical picture that has softened in the short term, with the price slipping below its 20- and 50-day averages and MACD negative, even as the longer-term trend remains intact. Overall, a low-leverage, reasonably valued business with a near-term cash conversion watch item.
Crystalvue Medical Co Ltd (6527) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.85B
- Dividend Yield
- 3.98%
- Average Volume (3M)
- 18.03K
- Price to Earnings (P/E)
- 12.1
- Beta (1Y)
- 0.20
- Revenue Growth
- -1.23%
- EPS Growth
- 10.20%
- Country
- TW
- Employees
- 109
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Crystalvue Medical Co Ltd Business Overview & Revenue Model
Company Description
Based in Taoyuan City, Taiwan, and established in 2009, Crystalvue Medical Corporation operates internationally, specializing in the design, production, and distribution of ophthalmic medical devices. Their comprehensive product range encompasses ins...
Crystalvue Medical Co Ltd Financial Statement Overview
Summary
Crystalvue combines steady revenue growth (NT$504m in 2020 to NT$949m today), expanding margins (gross ~35%, operating ~19%, net ~15.5%) and record net income of NT$147m with a near debt-free balance sheet — equity funds ~79% of assets and debt-to-equity is about 0.01, while ROE has improved to roughly 14%. The clear offset is cash conversion: operating cash flow slipped to NT$139m despite higher profits, and heavier capital spending pushed free cash flow to negative NT$46m from positive NT$21m a year earlier. The strong balance sheet makes this investment phase affordable, but the payback remains to be proven.
Income Statement
80PositiveBalance Sheet
88Very PositiveCash Flow
50Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 874.21M | 949.05M | 868.03M | 823.96M | 795.46M | 721.61M |
| Gross Profit | 322.82M | 331.88M | 299.14M | 266.75M | 261.74M | 211.39M |
| EBITDA | 184.71M | 198.76M | 189.36M | 149.73M | 169.59M | 151.22M |
| Net Income | 148.53M | 146.98M | 127.15M | 103.40M | 115.03M | 77.24M |
Balance Sheet | ||||||
| Total Assets | 1.36B | 1.30B | 1.18B | 1.08B | 1.01B | 938.51M |
| Cash, Cash Equivalents and Short-Term Investments | 84.02M | 132.02M | 241.64M | 276.36M | 178.55M | 200.78M |
| Total Debt | 38.25M | 11.70M | 18.46M | 25.03M | 31.41M | 37.61M |
| Total Liabilities | 323.96M | 266.79M | 246.39M | 221.37M | 237.32M | 219.61M |
| Stockholders Equity | 1.03B | 1.03B | 938.53M | 857.06M | 775.66M | 718.90M |
Cash Flow | ||||||
| Free Cash Flow | -41.08M | -46.06M | 21.01M | 145.47M | 42.75M | -288.70M |
| Operating Cash Flow | 161.19M | 139.13M | 153.06M | 154.01M | 51.76M | 63.26M |
| Investing Cash Flow | -206.10M | -184.98M | -128.63M | -9.12M | -4.52M | -193.91M |
| Financing Cash Flow | -33.88M | -63.78M | -56.13M | -48.09M | -64.47M | -39.44M |
Crystalvue Medical Co Ltd Peers Comparison
Overall Rating
- TW:652773Outperform
TW:415369Neutral
TW:411662Neutral
TW:651759Neutral
TW:679640Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6527 | 73Outperform | TWD 1.86B | 12.15 | ― | 3.98% | -1.23% | 10.20% |
| TW:4153 | 69Neutral | TWD 1.74B | 15.93 | ― | 6.48% | 9.73% | 36.89% |
| TW:4116 | 62Neutral | TWD 1.82B | 2.38 | ― | 4.91% | 3.85% | 786.65% |
| TW:6517 | 59Neutral | TWD 1.71B | 22.31 | ― | 2.72% | -16.82% | 31.08% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6796 | 40Underperform | TWD 2.04B | 123.00 | ― | 0.51% | 12.26% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6527 | Crystalvue Medical Co Ltd | 72.90 | -5.63 | -7.16% | |
| TW:4116 | BenQ Medical Technology Corp. | 40.70 | -3.48 | -7.87% | |
| TW:4153 | Diva Laboratories, Ltd. | 30.85 | -1.42 | -4.41% | |
| TW:6517 | Baso Precision Optics Ltd. | 55.20 | -3.46 | -5.90% | |
| TW:6796 | Medimaging Integrated Solution Inc. | 49.20 | -40.22 | -44.98% | |
| TW:7881 | Eyecare Tech, Inc. | 73.20 | -35.89 | -32.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026